Why access to medical innovations?

Lack of access to many medicines, for example for hepatitis C, HIV and tuberculosis, has been a major problem for low- and middle-income countries for decades. The Covid-19 pandemic has once again highlighted the unequal global access to life-saving medical products. This disparity leads to a dire amount of avoidable deaths, suffering and disruption of societies. 

There is a need to create an enabling environment to increase access to medicines, especially for low- and middle-income countries. 

Advocacy towards high-income governments

Along with consortium partners Wemos, Knowledge Ecology International and Innovarte and featuring contributions from sub-contractors Medicines Law & Policy, Universities Allied for Essential Medicines (UAEM), and Afya na Haki, we raise awareness towards high-income governments and multilateral organisations as their policies have a major impact on access to medicines for low- and middle-income countries. Through combined advocacy efforts, we push to improve access to medicines, whether through appropriate policy frameworks, sharing of intellectual property, knowledge and data, market transparency, adequate conditions to public funding of medicine research and development, and a support system of international agreements.  

Discover our consortium-produced knowledge products below, including reports, policy briefs, and more.